P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY

P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY

Bibliographic Details
Main Authors:	I. Schwaner, H. Hebart, C. Losem, T. Wolff, K. Famulla, J. Huelsenbeck, B. Schmidt, T. Nösslinger, D. Rossi
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845472.00847.e1

Similar Items

P646: EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH RITUXIMAB (VENR) IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY
by: I. Schwaner, et al.
Published: (2022-06-01)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
by: Ingo Schwaner, et al.
Published: (2023-08-01)

P649: SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.
by: Schwaner Ingo, et al.
Published: (2023-08-01)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
by: Ester Lovato, et al.
Published: (2023-04-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Verve 20
by: REA Editor
Published: (2011-12-01)

verve 27
by: REA Editor
Published: (2015-07-01)

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL
by: Joanna Rhodes, et al.
Published: (2023-08-01)

Spotlight on the expanding role of miR-647 in human cancers
by: Mohammadmahdi Jalili, et al.
Published: (2023-01-01)

verve 40-2021
by: Editor REA
Published: (2021-11-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

revista verve 25 – 2014
by: REA Editor
Published: (2014-09-01)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
by: Jacopo Olivieri, et al.
Published: (2022-06-01)

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
by: Loïc Ysebaert, et al.
Published: (2023-08-01)

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: O Al-Sawaf, et al.
Published: (2023-10-01)

Ronsard et la verve licencieuse
by: Sangoul Ndong
Published: (2014-12-01)

Ronsard et la verve licencieuse
by: Sangoul Ndong
Published: (2014-12-01)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
by: Arnon Kater, et al.
Published: (2023-08-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

Revistas: Verve 15 | Margem Esquerda 13
by: Antonio Ozaí da Silva
Published: (2009-06-01)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

CONCOMITANT USE OF VENETOCLAX 100 MG AND KETOCONAZOLE TO TREAT CLL IN A PUBLIC CENTER IN BRAZIL
by: FM Marques, et al.
Published: (2023-10-01)

Revistas: Lutas Sociais 21/22 - Verve 16
by: REA Editor
Published: (2009-11-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm
by: Ankit Mitesh Shah, et al.
Published: (2023-01-01)

Verve 31 - revista semestral autogestionária do nu-sol
by: REA Editor
Published: (2017-07-01)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
by: J. N. Allan, et al.
Published: (2022-06-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

Diagnostic and prognostic value of long non-coding RNA PROX1‑AS1 and miR-647 expression in gastric cancer
by: E. A. Vetchinkina, et al.
Published: (2022-12-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

S140: SINGLE-CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA-PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY
by: R. Thijssen, et al.
Published: (2022-06-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

RİCHTER SYNDROME TRANSFORMATİON UNDER VENETOCLAX TREATMENT: A CASE REPORT OF A 51-YEAR-OLD FEMALE WİTH CLL
by: İbrahim Halil Açar, et al.
Published: (2023-10-01)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
by: Timothy Woo, et al.
Published: (2023-10-01)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
by: Marco V. Haselager, et al.
Published: (2023-06-01)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: J. C. Barrientos, et al.
Published: (2022-06-01)